Le Registre des lobbyistes
Pfizer Canada ULC
Objets poursuivis : Renseignements rétrospectifs : | Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants. |
Objets poursuivis : Renseignements prospectifs : | Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants. |
Catégories | Description |
---|---|
Règlement | Access to Information Act & Regulations |
Proposition législative, Règlement | C-51 (An Act to Amend to Food and Drugs Act) Regulations |
Politique ou programme | Canadian Institute of Health Researchers (CIHR) and other Research Oriented Spending Programs |
Politique ou programme | Canadian Strategy for Cancer Control |
Subvention, Contribution ou autre avantage financier | CIHR Grants |
Règlement | Clinical Trials Regulations (Division 5) |
Politique ou programme | Common Drug Review Policies |
Proposition législative, Politique ou programme | Competition Act Amendments, Competition Bureau Studies |
Politique ou programme | Cross Border Trade |
Règlement | Data Protection/Patented Medicines Notice of Compliance Regulations [PM(NOC) Regulations] |
Proposition législative | Drug Product Review & Approval System |
Règlement | Drug Product Review & Approval System / Regulations (filing formats of drug submissions, i.e. electronic Common Technical Document (eCTD) providing review tools currently not listed in the regulations) |
Politique ou programme | Federal Provincial Pharmaceutical Initiatives |
Politique ou programme | Federal Tobacco Control Strategies |
Règlement | Food & Drug Regulations (Good Manufacturing Practices & Establishment Licensing) |
Règlement | Food & Drugs Act (Drug Review & Approval regulations, Amendments to FDA, Data protection, Direct-to-Consumer Advertising Regs, New Substance Notification Regulations, Clinical Registry and Disclosure Regulation) |
Proposition législative | Food and Drugs Act (Cross Border Trade [CBT], Drug Export Restrictions) |
Politique ou programme | Generic Pricing Policies |
Politique ou programme | Health Canada Pharmaceutical Policies and Guidelines |
Politique ou programme | Health Canada Probationary / Progressive Licensing Framework |
Politique ou programme | Health Canada Site Inspections' program |
Politique ou programme | Health Canada Subsequent Entry Biologics Policies |
Subvention, Contribution ou autre avantage financier | Health Partners International Canada (HPIC) - Tax Credit for Pharmaceutical Donations |
Politique ou programme | Improving the efficiency of the drug review and approval process (Health Canada's Blue Print/Progressive Licensing Framework) |
Politique ou programme | National Pharmaceutical Strategy |
Politique ou programme | Non-Insured Health Benefits (NIHB) |
Règlement | Patent Act (Patented Medicines (Notice of Compliance)) Regulations - Amendments to prices review board |
Règlement, Projet de loi ou résolution | Patented Medicine Prices Review Board (PMPRB) Regulations |
Politique ou programme | Post-Marketing Surveillance Initiatives |
Politique ou programme | Science and Technology Policy |
Politique ou programme | Veterans Affairs Drug Benefits Plan |
Politique ou programme | Veterinary Drug Distribution (VDD) post- NOC (Notice of compliance) Manufacturing changes guidelines |
Proposition législative | Veterinary Drug Distribution (VDDs) Document on Antimicrobial Categorization |